


JFW



Serial No. 10/747,715

Docket No. 133658-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: M. Montalto et al.

Group Art Unit:

Serial No.: 10/747,715

Examiner:

Filed: December 26, 2003

For Compositions and Methods for Noninvasive Imaging
of Soluble Beta-Amyloid

INFORMATION DISCLOSURE STATEMENT

- ☒ 1 **Pursuant to 37CFR 1.97(b)**
[within 3 months of national, non-CPA filing or prior to 1st Office Action] *no charge*
- ☐ 2 **Certification Pursuant to 37 CFR 1.97(c)(1)**
[before Final Office Action, Allowance, or other action closing prosecution] *no charge*
- ☐ 3 **Fee Payment Pursuant to 37 CFR 1.97(c)(2)**
[before Final Office Action, Allowance, or other action closing prosecution] *\$180.00*
- ☐ 4 **Certification & Fee Payment Pursuant to 37 CFR 1.97(d)**
[On or before issue fee payment] *\$180.00*

ATTN: BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The following are submitted in the above application in compliance with 37 CFR 1.97 and 37 CFR 1.98:

- ☒ 5 A list of documents on form PTO-1449 or Substitute together with copies of each identified document and a translation thereof or a concise explanation of each non-English language document or a Search Report from an International Searching Authority for a patent application filed via the Patent Cooperation Treaty or document(s) cited in the application or the priority application.

| | |
|--|--------------------|
| I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below. | |
| _____ | Date of Deposit |
| _____ | Type or Print Name |
| _____ | Signature |

This paper is submitted in accordance with:

- ☒ 6 37 CFR 1.97(b): [within 3 months of national, non-CPA filing or prior to 1st Office Action]
- ☐ 7 37 CFR 1.97(c): [before Final Office Action, Allowance, or other action closing prosecution, whichever is earlier]; and
- ☐ 8 The required Certification made in item 11 below; or
- ☐ 9 The \$180.00 fee specified in 37 CFR 1.17(p) for submission of this Information Disclosure Statement is authorized in item 15 below.
- ☐ 10 37 CFR 1.97(d): [on or before issue fee payment]; and
- a) The required Certification is stated in item 11 below; and
- b) The \$180.00 fee specified in 37 CFR 1.17(p) for submission of this Information Disclosure Statement is authorized in item 14 below.

☒ 11 Certification

- ☐ 12 Each item of information contained in this Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of this Statement; or
- ☐ 13 No item contained in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing this document after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR 1.56(c) more than three (3) months prior to the filing date of this Statement.

☒ 14 Payment of all applicable fees:


- ☒ 15 Please charge all applicable fees associated with the submittal of this Information Disclosure Statement to Deposit Account No. 07-0868

An original and two (2) copies of this document are enclosed.

July 14, 2004
Date

General Electric Company
CRD Patent Docket Rm 4A59
P.O. Box 8, Bldg. K-1
Schenectady, New York 12301
Customer Number: 006147

Respectfully submitted,


Attorney - Kimberly H. Parker

Registration No. 47,843
Phone: (518) 387-5448
or (518) 387-7122

FORM PTO-1449
(REV. 7-80)
(Title Amended 3/83)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

133658-3

SERIAL NO.

10/747,715

INFORMATION DISCLOSURE STATEMENT BY APPLICANT--

LIST OF ITEMS

Applicant

M. Montalto et al.

Filing Date

December 26, 2003

Group

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|------------------|----------|----------------------|-------|----------|-------------------------------|
| | AA 4 5 6 0 5 3 4 | 12/24/85 | Kung et al. | | | |
| | AB 5 2 3 1 0 0 0 | 07/27/93 | Majocha et al. | | | |
| | AC 5 2 7 2 0 5 5 | 12/21/93 | Haley | | | |
| | AD 5 5 2 0 9 0 4 | 05/28/96 | Nosco et al. | | | |
| | AE 5 7 2 1 1 3 0 | 02/24/98 | Scubert et al. | | | |
| | AF 5 7 5 0 3 4 9 | 05/12/98 | Suzuki et al. | | | |
| | AG 5 8 1 1 3 1 0 | 09/22/98 | Ghanbari et al. | | | |
| | AH 5 8 3 7 6 7 2 | 11/17/98 | Schenk et al. | | | |
| | AI 6 0 5 4 1 1 4 | 04/25/00 | Lansbury, Jr. et al. | | | |
| | AJ 6 1 1 4 1 3 3 | 09/05/00 | Seubert et al. | | | |
| | AK 6 1 1 4 1 7 5 | 09/05/00 | Klunk et al. | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|---|------------------|----------|---------|-------|----------|-------------|----|
| | | | | | | YES | No |
| ✓ | AL 8 9 0 6 2 4 2 | 07/13/89 | PCT | | | | |
| ✓ | AM 9 3 0 4 1 9 4 | 03/04/93 | PCT | | | | |
| ✓ | AN 9 7 4 1 8 5 6 | 11/13/97 | PCT | | | | |
| ✓ | AO 9 8 2 7 9 7 2 | 07/02/98 | PCT | | | | |
| ✓ | AP 0 1 8 7 3 5 4 | 11/22/01 | PCT | | | | |

OTHER INFORMATION (Including Author, Title, Date, Pertinent pages. Etc.)

| | |
|----|--|
| AR | US2002/0159947A1 - 10-31-02 - Zaczek et al. - "Use of Small Molecule Radioligands to Discover Inhibitors of Amyloid-Beta Peptide Production and for iagnostic Imaging" |
| AS | US2002/0182152A1 - 12-5-02 - Goldstein et al. - Ocular Diagnosis of Alzheimer's Disease" |
| AT | |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)
(Title Amended 3/83)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

133658-2

SERIAL NO.

10/747,715

INFORMATION DISCLOSURE STATEMENT BY APPLICANT--
LIST OF ITEMS

(Use several sheets if necessary)

Applicant

M. Montalto et al.

Filing Date

December 26, 2003

Group

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|-----------------|---|---|---|---|---|---|---|----------|-------------------|-------|----------|-------------------------------|
| | BA | 6 | 1 | 3 | 3 | 2 | 5 | 9 | 10/17/09 | Klunk et al. | | | |
| | BB | 6 | 1 | 6 | 8 | 7 | 7 | 6 | 01/02/01 | Klunk et al. | | | |
| | BC | 6 | 2 | 7 | 4 | 1 | 1 | 9 | 08/14/01 | Barrio et al. | | | |
| | BD | 6 | 3 | 3 | 1 | 4 | 4 | 0 | 12/18/01 | Nondstredt et al. | | | |
| | BE | | | | | | | | | | | | |
| | BF | | | | | | | | | | | | |
| | BG | | | | | | | | | | | | |
| | BH | | | | | | | | | | | | |
| | BI | | | | | | | | | | | | |
| | BJ | | | | | | | | | | | | |
| | BK | | | | | | | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|----|-----------------|--|--|--|--|--|--|--|------|---------|-------|----------|-------------|----|
| | | | | | | | | | | | | | | YES | No |
| | BL | | | | | | | | | | | | | | |
| | BM | | | | | | | | | | | | | | |
| | BN | | | | | | | | | | | | | | |
| | BO | | | | | | | | | | | | | | |
| | BP | | | | | | | | | | | | | | |

OTHER INFORMATION (Including Author, Title, Date, Pertinent pages. Etc.)

| | | |
|--|----|--|
| | BR | |
| | BS | |
| | BT | |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)
(Title Amended 3/83)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

133658-2

SERIAL NO.

10/747,715

INFORMATION DISCLOSURE STATEMENT BY APPLICANT--
LIST OF ITEMS

(Use several sheets if necessary)

Applicant

M. Montalto et al.

Filing Date

12/26/03

Group

OTHER INFORMATION (Including Author, Title, Date, Pertinent pages. Etc)

| | | |
|--|-----------|---|
| | AU | Wen-hong Li, et al. "Mechanistic Studies of a Calcium-Dependent MRI Contrast Agent", Inorganic Chemistry, 2002, 41, pages 4018-4024 |
| | AV | Jean-Cosme Dodart, et al., "Immunization Reverses Memory Deficits Without Reducing Brain A β Burden in Alzheimer's Disease Model", Nature Neuroscience, Vol. 5, No. 5, May 2002, 452-457/ |
| | AW | Dominic M. Walsh, et al., "Naturally Secreted Oligomers of Amyloid Protein Potently Inhibit Hippocampal Long-Term Potentiation in vivo", Nature, April 4, 2002, Vol. 416, pages 535-539 |
| | AX | Ronald B. DeMattos, et al. "Brain to Plasma Amyloid- β Efflux: A Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease", Science, March 22, 2002, Vol. 295, pages 2264-2267 |
| | AY | Jongmin Kang, et al., "The Amide Derivatives of Chrysamine G Protect Human Astrocyte Cells Against A β -Induced Toxicity", Bulletin of the Korean Chemical Society, March 20, 2002, Vol. 23, No. 3, pages 363-364 |
| | AZ | Nancy A. DeZutter et al. "To Mama-Chrysamine G, A Probe for Beta-Amyloid Protein of Alzheimer's Disease", European Journal of Nuclear Medicine, 1999, Vol. 26, No. 11, pages 1392-1399. |
| | BU | Jongmin Kang, et al. "The Amide Derivatives of Chrysamine G Bind to the β -Amyloid Fibril", Bull. Korean Chem. Soc., 2001, Vol. 22, No. 10, pages 1065-1066 |
| | BV | Rakez Kaye, et al. "Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis", Science, April 18, 2003, Vol. 300, pages 486-489 |
| | BW | Ralph Weissleder, et al., "In Vivo Imaging of Tumors with Protease-Activated Near-Infrared Fluorescent Probes", Nature Biotechnology, April 17, 1999, Vol. 17, pages 375-378 |
| | BX | Angelique Y. Louie, et al. "In Vivo Visualization of Gene Expression Using Magnetic Resonance Imaging", Nature Biotechnology, March 2000, Vol. 18, pages 321-326 |
| | BY | |
| | BZ | |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.